FDMT NASDAQ
Credit Risk of going bust: lower than 52% of companies Debt: 5.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.05 (down 99.5%), 4D Molecular Therapeutics, Inc. would be worth roughly what it owes.
Total debt $39.2M against a stock market value of $660.7M.
Distance to default 5.30 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $9.8M (short-term plus half of long-term), stock volatility 76.2%; Altman Z'' 1.20. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
EmeryVille, CA 94608
US
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bizily Scott | M-Exempt | 1,635 | $4.14 | 2026-10-16 |
| Bizily Scott | S-Sale | 1,635 | $12.84 | 2026-10-16 |
| Bizily Scott | M-Exempt | 1,635 | $4.14 | 2026-10-16 |
| Kirn David | S-Sale | 58,061 | $12.92 | 2026-10-05 |
| Kirn David | S-Sale | 272 | $13.61 | 2026-10-05 |